

ASX RELEASE

11 August 2023

KAZIA THERAPEUTICS LIMITED (ASX: KZA; NASDAQ: KZIA) – CLEANSING NOTICE

This updated notice is given by Kazia Therapeutics Limited (**Kazia**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

Reference is made to the Appendix 2A released to ASX on 11 August 2023 relating to the issue of 15,000 fully paid ordinary shares (**New Shares**) to existing shareholders at an issue price of USD 0.11 per New Share.

In accordance with section 708A(6) of the Corporations Act, Kazia advises that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Kazia has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to Kazia; and
 - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) or 708A(8) of the Corporations Act.

Yours sincerely



Anna Sandham
Company Secretary

Board of Directors

Dr John Friend Executive Chair and Chief Executive Officer
Mr Bryce Carmine Non-Executive Director
Mr Steven Coffey Non-Executive Director
Ms Ebru Davidson Non-Executive Director